At the Canadian Association for Population Therapeutics (CAPT) Annual Conference, Sumeet Singh, Senior Director, EVERSANA, delivered a presentation on pharmacoeconomic analysis and outcome-based agreements and what they mean for Canadian private payers.
Watch his session below for answers to the following questions:
- Are pharmacoeconomic analyses relevant for private payers?
- Should pharmacoeconomic analyses for private payers differ from those for HTA/public payers?
- Should a societal or health system perspective be considered at all by private payers?
EVERSANA employs a team of over 2500 professionals across 27 locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…